AzTrials
AzTrials

Hospital ReadmissionAIRTIGHTNCT02763202

Aiming to Improve Readmissions Through InteGrated Hospital Transitions

A study testing CHS Transition Services in people with Hospital Readmission, run by Wake Forest University Health Sciences at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to better enhance transitions of care for the highest risk, complex patients, Carolinas HealthCare System (CHS) has designed an Integrated Practice Unit, called Transition Services (CHS-TS).CHS-TS aims to improve patient outcomes through innovative approaches that leverage analytics and… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Hospital Readmission
What is being tested?
CHS Transition Services
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,876 participants
Where
1 siteUnited States
Study dates
8 Feb 2016to 30 Apr 2017
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Classified as inpatient or observation as of (00:00), and
  • Predixion score ≥ 0.50, and
  • Carolinas Hospitalist Group is listed as the primary attending service or consulting service at CMC Main or Mercy campuses, and
  • Not discharged at the time of list generation.

Who cannot join

  • Randomized in the last 90 days into either the CHS-TS or to usual care
  • Not a North Carolina resident
  • Greater than 2.5 hour drive time from CMC to primary residence
  • Psychiatric diagnosis codes within the last 6 months including: Schizophrenia, Suicidal Ideation, Homicidal Ideation, or Psychosis (ICD10 - R45.851, R45.850, F20.x-F29.x)
  • Diagnosis of sickle cell anemia in the past year (ICD10 - D57)
  • Diagnosis of drug or alcohol dependence within the last 90 days (ICD10 - F10.2x, F11.2x, F12.2x, F13.2x, F14.2x, F16.2x, F18.2x, F19.2x)
Show all 15Show fewer
  • Actively followed for a primary diagnosis of cancer (greater than 2 visits to CHS Cancer Center or on chemotherapy in last 2 months)
  • Hospitalized for greater than 72 hours
  • Residing in a facility prior to admission (example jail or skilled nursing facility)
  • Under the care of hospice prior to admission
  • Left Against Medical Advice*
  • Disposition other than home (example skilled nursing facility or rehabilitation facility)*
  • Disposition home with hospice*
  • Heart Failure as a discharge diagnosis *
  • This exclusion criterion will only be applied during the analysis.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Carolinas Medical Center

    Charlotte, North Carolina, 28226

Other trials in United States

About this study

The purpose of this study is to better enhance transitions of care for the highest risk, complex patients, Carolinas HealthCare System (CHS) has designed an Integrated Practice Unit, called Transition Services (CHS-TS).CHS-TS aims to improve patient outcomes through innovative approaches that leverage analytics and technology, while bridging care coordination and communication gaps. During their hospitalization, CHS-TS patients enter into a transition pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support. AIRTIGHT (Aiming to Improve Readmissions Through InteGrated Hospital Transitions) is a pragmatic, randomized quality improvement evaluation, which seeks to evaluate the effects of the role-out of CHS-TS services for patients at high risk for a 30-day readmission. AIRTIGHT will test the hypothesis that patients that receive care through CHS-TS will have a lower all cause, 30-day readmission rate than patients that receive usual care.

Read the detailed description

BACKGROUND

Hospital inpatient care accounts for the largest share of total health care expenses in the US. In 2012, the average cost per inpatient stay was $10,400 with total aggregated hospital costs of $377.5 billion. (Moore, 2012; and Weiss, 2012) In addition to this expense, transitions from the hospital represent a particularly vulnerable time when patients are susceptible to experiencing adverse events, which is especially true for patients with complex chronic comorbidities. For example, twenty percent of Medicare patients are readmitted to the hospital within 30 days, and 20% of all discharged patients suffer from a preventable adverse event within three weeks of discharge.(Rennke, 2013) Despite national efforts to improve transitions, the hospital discharge process largely remains chaotic, fragmented, and associated with poor outcomes. (Rennke, 2013; Hansen, 2011; Jack, 2009; Kansagara, 2015; Kansagara, 2011; \& Kripalani, 2014). Currently, even the highest risk patients leave a complex, acute hospital stay to then arrive in primary care offices that are often neither equipped nor resourced to manage the challenges inherent to such transitions. Indeed, transitioning the highest risk, complex patients will require a paradigm shift in care delivery that is intensive, multidisciplinary, coordinated, and encompasses wrap-around services.(http://www.isc.hbs.edu/health-care/vbhcd/Pages/integrated-practice-units.aspx.)

RATIONALE

To better enhance transitions of care for the highest risk, complex patients, Carolinas HealthCare System (CHS) has designed an Integrated Practice Unit, called Transition Services (CHS-TS). The IPU model is based on the concept that significant improvements in outcomes will come from physician-led, team based, integrated services that are focused on a specific condition or segment of the population.(http://www.isc.hbs.edu/health-care/vbhcd/Pages/integrated-practice-units.aspx) Also integral to the IPU model is having an advanced informatics platform to continuously measure costs, processes, and patient outcomes. CHS-TS aims to improve patient outcomes through innovative approaches that leverage analytics and technology, while bridging care coordination and communication gaps. During their hospitalization, CHS-TS patients enter into a transition pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support. Because this population faces many barriers to accessing traditional care, CHS-TS leverages virtual technology to provide visits with patients in their home setting when necessary and appropriate. Whether virtual or in person, each patient will receive the following seven core components (the first four of which will be used as markers for the implementation (RE-AIM) evaluation:

(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge

CHS strives to provide extraordinary care to patients and the communities it serves. This proposed evaluation is designed to guide CHS strategy and quality improvement by applying research methodology and data analytics to support the environment of a Learning Health System. Ultimately, as CHS deploys resource intensive interventions like the CHS-TS, it is important for the system and its patients to know answers to questions such as: What type of patient does the CHS-TS help?; How much benefit might be expected?; and At what cost?

AIRTIGHT (Aiming to Improve Readmissions Through InteGrated Hospital Transitions) is a pragmatic, randomized quality improvement evaluation, which seeks to evaluate the effects of the role-out of CHS-TS services for patients at high risk for a 30-day readmission. This outcomes evaluation of a quality improvement intervention is designed to be a seamless part of the routine care in a real-world setting.

INVESTIGATIONAL PLAN

Overall Study Design

AIRTIGHT is a pragmatic, randomized quality improvement evaluation. Patients who are identified by risk modeling as having a high risk (>20%) for a 30-day readmission will be eligible for CHS-TS referral (referral eligible). Each weekday, referral eligible patients will be randomly assigned to CHS-TS referrals with a total number targeted to the CHS-TS's capacity. The CHS TS capacity will be revaluated on a daily. Because variables that affect eligibility may change throughout the course of a hospital stay, exclusion criteria are applied again at the time of discharge for the purposes of analysis. For example, patients not discharged to home are excluded. A diagnosis of heart failure is also added as an additional exclusion criterion at the time of discharge because CHS Heart Success recruits patients from a similar population and there is significant overlap in the services offered between CHS TS and CHS Heart Success. All patients who remain eligible at the time of discharge (discharge eligible) will be included in the analysis. Planned enrollment is 1520 patients (n=760 per arm) with the engagement in CHS-TS services ending at the 30th day after discharge. Outcomes data will be tracked for 90 days. To mitigate the risk of selection bias, all eligibility criteria are objective and determined using data analytics within the software package, SAS. Additionally, analysis will be by intention to treat. With the use of this pragmatic design, crossovers from the CHS-TS arm to usual care are expected and may attenuate the measured effect of the CHS-TS. Since this evaluation protocol is part of a quality improvement intervention, the investigators requested that the CHS institutional review board designate the study as expedited research and grant a waiver of informed consent.

Primary Outcome Variable

30-day all cause readmission with index visit as defined by the Centers for Medicaid and Medicare Services (CMS) and with inclusion of observation patients at any CHS facility

Secondary Outcome Variable(s)

  1. 30-day all cause CHS readmission (as defined by CMS)
  2. Length of stay upon the index visit
  3. Length of stay upon the readmission visit
  4. All cause, 60 and 90-day readmission rate as defined by CMS with inclusion of observation patients at any CHS facility
  5. 30-day readmission rate among patients with a primary diagnosis of congestive heart failure
  6. 30-day readmission rate among patients with a primary diagnosis of pneumonia
  7. 30-day readmission rate among patients with a primary diagnosis of sepsis
  8. Number of Emergency Department visits within 30 days of discharge
  9. Intensive Care Unit visits

Independent and Dependent Variable(s)

The dependent variable under assessment is 30-day all cause readmission (yes/no). The primary independent variable of interest is the program assignment (usual care vs. CHS-TS).

Subject Selection

Selection will be through an automated process that generates a referral list at 03:00 of patients admitted during the preceding 24 hour period, called the CHS-TS Referral Eligible List (REL). At the CMC Main campus, where patient enrollment occurs Monday through Friday, the Monday REL contains admissions that meet criteria from Friday-Sunday. At the CMC Mercy campus, where patient enrollment occurs Tuesday through Friday, the Tuesday REL contains admissions that meet criteria from Friday-Monday. The REL is generated based on the study's inclusion/exclusion criteria.

Randomization

Patients that meet the eligibility criteria at the time of admission will be randomized into one of two groups on the CHS-TS Referral Eligible List (REL). A constrained randomization scheme will be utilized allocating referrals into permuted blocks each day for up to 30 total referrals (total includes CHS-TS and usual care). The total referrals are based on daily estimates of clinic capacity. The allocation will be 1:1 CHS-TS: usual care.

Being tested
CHS Transition Services
Keywords
transition of care, pragmatic clinical trial, telemedicine, emergency medical technician

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CHS Transition ServicesOther

    The CHS Transition Services (CHS-TS) pathway includes the following seven components:

    (i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge

Study groups in NCT02763202
Study groupRoleWhat they receive
Usual Care GroupNo interventionParticipants assigned to the usual care group will continue have the current standard of care including any discharge services for example those usually arranged by case managers, hospitalists, and primary care physicians.
CHS-TS GroupExperimentalParticipants assigned to the Carolinas Healthcare Services Transition Services (CHS-TS) group will be introduced to a patient navigator prior to discharge from the hospital and if interested enter the CHS-TS pathway that includes the following key services: integrated access to medical, pharmacist, and specialty providers; access to CHS disease specific management programs; dedicated care management services delivered in home and at the clinic; lab and infusion services; palliative care consultations when appropriate; and paramedicine for 24 hour support.
Receives: Other: CHS Transition Services

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 30-day all cause CHS readmission

    Index visit as defined by the Centers for Medicaid and Medicare Services (CMS) and inclusion of observation patients at any CHS facility

    Measured: 30 days from index visit

Secondary outcomes (4)
  1. 30-day all cause CHS readmission

    Index visit as defined by CMS at any CHS facility

    Measured: 30 days from index visit

  2. Length of stay upon the index visit

    Length of stay begins at time stamp of the admission order and ends at time stamp created at hospital discharge.

    Measured: Length of stay upon the index visit, will be measured up to 1 month.

  3. Length of stay upon the readmission visit

    Length of stay begins at time stamp of the admission order and ends at time stamp created at hospital discharge.

    Measured: Length of stay upon the first readmission after index visit, will be measured up to 1 month.

  4. All cause, 60 and 90-day readmission rate

    Index visit defined by CMS and inclusion of observation patients at any CHS facility

    Measured: 60 and 90 days from index visit

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted5 May 2016 (estimated)
  2. Study start8 Feb 2016
  3. Primary completion31 Jan 2017
  4. Study completion30 Apr 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
1,876 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02763202
Sponsor's protocol ID
01-16-17E
Acronym
AIRTIGHT
Status last verified
Feb 2018
First submitted
3 Mar 2016
Last updated
27 Apr 2022
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Moore B, Levit K, Elixhauser A. Costs for Hospital Stays in the United States, 2012. 2014 Oct. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Statistical Brief #181. Available from http://www.ncbi.nlm.nih.gov/books/NBK259217/

    PubMed 25521003
  • Weiss AJ, Elixhauser A. Overview of Hospital Stays in the United States, 2012. 2014 Oct. In: Healthcare Cost and Utilization Project (HCUP) Statistical Briefs [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2006 Feb-. Statistical Brief #180. Available from http://www.ncbi.nlm.nih.gov/books/NBK259100/

    PubMed 25506966
  • Rennke S, Nguyen OK, Shoeb MH, Magan Y, Wachter RM, Ranji SR. Hospital-initiated transitional care interventions as a patient safety strategy: a systematic review. Ann Intern Med. 2013 Mar 5;158(5 Pt 2):433-40. doi: 10.7326/0003-4819-158-5-201303051-00011.

    PubMed 23460101
  • Hansen LO, Young RS, Hinami K, Leung A, Williams MV. Interventions to reduce 30-day rehospitalization: a systematic review. Ann Intern Med. 2011 Oct 18;155(8):520-8. doi: 10.7326/0003-4819-155-8-201110180-00008.

    PubMed 22007045
  • Jack BW, Chetty VK, Anthony D, Greenwald JL, Sanchez GM, Johnson AE, Forsythe SR, O'Donnell JK, Paasche-Orlow MK, Manasseh C, Martin S, Culpepper L. A reengineered hospital discharge program to decrease rehospitalization: a randomized trial. Ann Intern Med. 2009 Feb 3;150(3):178-87. doi: 10.7326/0003-4819-150-3-200902030-00007.

    PubMed 19189907
  • Kansagara D, Chiovaro JC, Kagen D, Jencks S, Rhyne K, O'Neil M, Kondo K, Relevo R, Motu'apuaka M, Freeman M, Englander H. So many options, where do we start? An overview of the care transitions literature. J Hosp Med. 2016 Mar;11(3):221-30. doi: 10.1002/jhm.2502. Epub 2015 Nov 9.

    PubMed 26551918
  • Kansagara D, Englander H, Salanitro A, Kagen D, Theobald C, Freeman M, Kripalani S. Risk prediction models for hospital readmission: a systematic review. JAMA. 2011 Oct 19;306(15):1688-98. doi: 10.1001/jama.2011.1515.

    PubMed 22009101
  • Kripalani S, Theobald CN, Anctil B, Vasilevskis EE. Reducing hospital readmission rates: current strategies and future directions. Annu Rev Med. 2014;65:471-85. doi: 10.1146/annurev-med-022613-090415. Epub 2013 Oct 21.

    PubMed 24160939
  • McWilliams A, Roberge J, Anderson WE, Moore CG, Rossman W, Murphy S, McCall S, Brown R, Carpenter S, Rissmiller S, Furney S. Aiming to Improve Readmissions Through InteGrated Hospital Transitions (AIRTIGHT): a Pragmatic Randomized Controlled Trial. J Gen Intern Med. 2019 Jan;34(1):58-64. doi: 10.1007/s11606-018-4617-1. Epub 2018 Aug 14.

    PubMed 30109585
  • McWilliams A, Roberge J, Moore CG, Ashby A, Rossman W, Murphy S, McCall S, Brown R, Carpenter S, Rissmiller S, Furney S. Aiming to Improve Readmissions Through InteGrated Hospital Transitions (AIRTIGHT): study protocol for a randomized controlled trial. Trials. 2016 Dec 19;17(1):603. doi: 10.1186/s13063-016-1725-2.

    PubMed 27993163

Questions about this trial

What is this clinical trial studying?

A study testing CHS Transition Services in people with Hospital Readmission, run by Wake Forest University Health Sciences at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Apr 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

30-day all cause CHS readmission (time frame: 30 days from index visit). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02763202, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in